Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.

Oncotarget - 20 Dec 2016

Tury Sandrine, Becette Véronique, Assayag Franck, Vacher Sophie, Benoist Camille, Kamal Maud, Marangoni Elisabetta, Bièche Ivan, Lerebours Florence, Callens Céline

Abstract excerpt

COX-2 expression level and prognostic value are still a matter of debate in breast cancer (BC). We addressed these points in the context of PIK3CA mutational status. Based on an interesting study of aspirin efficacy in colorectal cancer, we hypothesized that celecoxib antitumoral activity may be restricted to PIK3CA mutated BC.COX-2 mRNA expression was analyzed in 446 BC samples and in 61 BC patient-derived...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Cyclooxygenase 2

Share to Cyclooxygenase 2 Inhibitors

Share to Mice, Nude

Share to Predictive Value of Tests

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27835884
DOI: 10.18632/oncotarget.13200
PMCID: PMC5356723

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.PMID 27835884Read ↗

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).Semantic proximity Read ↗

Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.Semantic proximity Read ↗

COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer CellsSemantic proximity Read ↗

Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis.Semantic proximity Read ↗

Dasatinib/Celecoxib combination: A new hope in triple negative breast cancer treatmentSemantic proximity Read ↗

Cyclooxygenase-2: a novel target for cancer chemotherapy?Semantic proximity Read ↗

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.Semantic proximity Read ↗

High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancerSemantic proximity Read ↗

The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.Semantic proximity Read ↗

Targeting cyclooxygenase‐2 for prevention and therapy of colorectal cancerSemantic proximity Read ↗

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.Semantic proximity Read ↗

Serum proteomic profiles suggest celecoxib-modulated targets and response predictors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.